 |
CLINICAL NEWS
Aspirin can reduce the risk for cancer-related mortality and can reduce or prevent the risk for distant metastasis, according to 3 new studies published online by The Lancet and The Lancet Oncology. » More |
Daily supplementation with antioxidants, vitamins E and C, and alpha acid, did not improve memory function in patients with Alzheimer’s disease, according to a new study. » More |
Editor's Pick
FDA user fee renewal addresses drug shortages, new drug development
Every 5 years, Congress is called on to reauthorize a series of user fees that support FDA oversight of drugs and medical products. The Prescription Drug User Fee Act and similar measures authorize fees to fund a number of FDA regulatory programs. This must-pass bill, however, creates a ready legislative vehicle for policy-makers to add on a host of pet FDA-related measures. » Click here. |
CONTINUING EDUCATION
Of the 35 new molecular entities approved by FDA in 2011, 17 are considered groundbreaking because of their potential to make a real difference in the lives of patients.
To read and print the article with TEST QUESTIONS, click here. To proceed to the online exams and earn up to 2 CPE credits, click here to login. |
PATIENT CARE
Enhanced pharmacist care for patients with dyslipidemia improves low-density lipoprotein cholesterol levels, according to a study published in the March issue of Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. » More |
ADHERENCE
Weekly mobile phone text messaging may help patients with human immunodeficiency virus adhere to antiretroviral therapy that is often associated with difficult side effects, according to a study published online March 14 in the Cochrane Database of Systematic Reviews. » More |
FDA News
FDA has approved beclomethasone dipropionate (QNASL Nasal Aerosol, Teva Pharmaceutical Industries), a “dry” nasal aerosol corticosteroid that treats year-round and seasonal nasal allergy symptoms in people aged 12 years and older. » More |
FDA has issued a complete response letter to dihydroergotamine (Levadex inhalation aerosol, MAP Pharmaceuticals) for the treatment of acute treatment of migraine in adults. » More |
Survey
Yes
No
Respond here and see what your colleagues think too.
Want to see the results of our last survey regarding who performs medication therapy management in your health system? Click here. |
|
Confirm your
e-newsletter subscription click here.
To ensure future delivery of email newsletters from Formulary please take a moment to confirm your subscription by clicking here.
Thank you,
Formulary Staff |
Digital Edition |
|
|
|
You are subscribed to %%list.name%% as %%emailaddr%%. Click here to unsubscribe or edit your member profile.
To ensure delivery to your inbox, please add us to your address book. If you need help doing this, Click here.
Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 866-529-2922 at any time, or
fax us at 218-740-6417. Outside the U.S., please phone 218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.
|
|
|